Abzu and NASA GeneLab study dermatological changes in spaceflight.
Abzu’s QLattice uniquely identified key “partner” genes involved in skin spaceflight response, a new discovery for how spaceflight damages skin.
Abzu identified which metabolites are present in early or late denning in bears.
Understanding how bears can hibernate without developing blood clots or muscle atrophy can help humans prepare for the future of space travel.
Abzu designed active and safe ASO and siRNA therapeutics.
A strategic partnership with Contera Pharma included ASO and siRNA therapeutic designs and target identification.
Abzu created a real-time LNP designer to predict apparent pKa value.
Our models, interfaced through an application, allowed scientists to modify LNP properties and observe the direct impact.
Abzu reveals early predictive response biomarkers in first-ever clinically viable Myc oncogene inhibitor by Peptomyc®.
Stratifying patients at pretreatment by answering the question: Can we distinguish which patients will respond to OMO-103 treatment at baseline?
Abzu discovered key biomarkers for successful clinical trial of siRNA therapeutic.
Simple models accurately predicted and explained key biomarkers for successful clinical trial test of siRNA designed to downregulate.
Abzu increased safe ASOs by 20% over-and-above the in-house model.
Abzu’s in-house activity models for RNA therapeutics are best-in-class for designing safe ASOs.
